Raising The Bar For Anticoagulants? Warfarin Genotype Results Announced
This article was originally published in The Gray Sheet
Executive Summary
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30% reduction in hospitalization rates from any cause within six months of starting the drug
You may also be interested in...
Studies Find Limited Support For Genotyping-Guided Warfarin Dosing
The overall message of three trials published recently in The New England Journal of Medicine: “This pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing,” according to an editorial also in NEJM.
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.